Beta 2 Microglobulin as a Biomarker in Peripheral Arterial Disease: Proteomic Profiling and Clinical Studies

Wilson, Andrew; Kimura, Eiichiro; Harada, Randall K; Narasimhan, Balasubramanian; Meng, Xiangyi; Zhang, Fujun; Beck, Kendall; Olin, Jeffrey W.; Fung, Eric T.; Cooke, John P.

doi:10.1016/j.hlc.2007.06.199

Cited by 41 publications

(70 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wilson et al describe plasma b2-microglobulin (B2M) as a specific biomarker of PAD, and show that B2M levels correlate with the severity of disease, as assessed by the ankle/brachial index (ABI) or by treadmill testing. Even after including renal function in a multivariate analysis, B2M remains a predictor of ABI and, interestingly, when the levels of this biomarker were assessed in a large cohort of patients with coronary artery disease (CAD) they were found to be higher only in CAD patients who also had PAD [47]. It is hypothesized that the reason for the specificity of B2M for PAD could be the repeated ischemia/ reperfusion insults generated by walking in patients with claudication [47], but this does not seem to be the case as the levels of this biomarker do not change immediately after maximal leg exercise [48].…”

Section: Biomarkers In Padmentioning

confidence: 99%

Matrix metalloproteinases and peripheral arterial disease

et al. 2009

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs), a family of enzymes that degrade extracellular matrix, are emerging as important modulators of atherothrombosis. MMPs are produced by inflammatory cells; some of them are also released by activated platelets and play a crucial role in the remodeling processes, leading to atherosclerotic plaque formation, plaque rupture, arterial aneurysm development, and critical limb ischemia. Independent from their matrix degrading activity, MMPs also regulate some cell functions relevant to atherothrombosis, such as platelet activation, neutrophil activation, and vascular reactivity. Plasma levels of some MMPs are increasingly being recognized as a biomarker of atherosclerosis and cardiovascular risk. In peripheral arterial disease, MMPs have been shown to be involved in angiogenesis, arteriogenesis, and the development of arterial calcifications. Increased plasma levels of some MMPs (MMP-2, MMP-9) have been correlated with PAD development and severity. Single nucleotide polymorphisms of the genes encoding for some MMPs have also been associated with the risk of developing peripheral arterial disease and critical limb ischemia. Large prospective observational studies are needed to further demonstrate the role of MMPs in PAD. In perspective, pharmacologic targeting of the expression or activity of MMPs may represent a novel, attractive approach for the treatment of peripheral arterial disease.

show abstract

Section: Biomarkers In Padmentioning

confidence: 99%

Matrix metalloproteinases and peripheral arterial disease

et al. 2009

View full text Add to dashboard Cite

show abstract

“…A few studies also supported the correlation between serum beta2 microglobulin levels and various cardiovascular risk factors, including CRP, in hemodialysis patients (Kuragano et al, 2010). And recently, beta2 microglobulin has been suggested to be a novel biomarker of peripheral arterial disease and an independent predictor of aortic stiffness in atherosclerosis, in the general population (Wilson et al, 2007). Additionally, higher serum beta2 microglobulin levels were proposed to be a novel marker to distinguish levels of risk in acute heart failure patients with creatinine ≤ 3mg/dl (Kawai et al, 2010).…”

Section: Beta 2 Microglobulinmentioning

confidence: 93%

Determinants of Cardiovascular Risk in Hemodialysis Patients Without Significant Comorbidities

Zümrütdal¹

2011

Progress in Hemodialysis - From Emergent Biotechnology to Clinical Practice

View full text Add to dashboard Cite

“…More recently, the development of clinically-applied mass spectrometry techniques [34] has further broadened the systems approach to CVD. By screening a large amount of different potential biomarkers, both proteomics (Table 2) [35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] and metabolomics (Table 3) [50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67] studies aimed at improving knowledge of CVD pathways. However, many factors precluded meaningful biological insights or practical prediction so that the value of these recent discoveries was currently viewed with skepticism [69].…”

Section: Clinical Perspectivesmentioning

confidence: 99%